PhagePro — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PhagePro is a private, pre-clinical stage biotech leveraging naturally occurring bacteriophages to create targeted antibacterial therapies, with an initial focus on cholera. The company differentiates itself through a strong commitment to global health equity, seeking to deploy its solutions in low-resource settings hardest hit by antibiotic resistance. While still early-stage and pre-revenue, it operates at the intersection of innovative science, public policy, and community-focused commercialization to tackle urgent public health threats.

Infectious Disease

Technology Platform

Utilizes naturally occurring bacteriophages (viruses that infect bacteria) to develop targeted antibacterial therapies, with a focus on addressing pathogens causing global health disparities.

Opportunities

The global antimicrobial resistance crisis creates a vast, unmet need for novel antibacterial solutions like phage therapy.

The company's focus on neglected diseases like cholera allows it to tap into funding from global health and philanthropic organizations dedicated to health equity.

Risk Factors

Regulatory pathways for standardized phage products are still developing.

The business model focusing on low-resource markets presents significant challenges in securing sustainable venture funding and requires mastering complex deployment logistics.

Competitive Landscape

PhagePro operates in the emerging phage therapy sector, competing with other biotechs like Armata Pharmaceuticals, Adaptive Phage Therapeutics, and Locus Biosciences, though these often focus on Western markets and personalized medicine. Its specific focus on global health diseases like cholera may face competition from academic/non-profit consortia and vaccine developers.

More companies in Biologics / Biosimilars →More companies in United States →